Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Endometrium Clear all
Completed Phase 2 Interventional

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

NCT04814108
View directory record Official record
Conditions
Uterine Serous Carcinoma
Interventions
Azenosertib
Drug
Lead sponsor
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
41
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 23, 2026, 10:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Marrow Cell Engraftment of the Uterus and Genetic Studies of Reproductive Functioning

NCT01468935
View directory record Official record
Conditions
Endometriosis, Stem Cell Transplant, Healthy Volunteers
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years and older · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 23, 2026, 10:08 AM EDT
Completed No phase listed Observational

Effects of Raloxifene on the Uterus and Ovaries of Premenopausal Patients

NCT00001837
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasm
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 10:08 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

NCT05036681
View directory record Official record
Conditions
Metastatic Cancer, Endometrium Cancer, Endometrial Carcinoma
Interventions
Futibatinib, Pembrolizumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 23, 2026, 10:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pre-Clinical Models in Gynecological Tumors A Tissue Repository

NCT00250783
View directory record Official record
Conditions
Endometrial Neoplasms, Uterine Neoplasms
Interventions
Not listed
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Jul 23, 2026, 10:08 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Endometrial Luteal Phase Characteristics and Luteal Phase Support in Controlled Ovarian Stimulation Protocols With GnRH Antagonists:Focusing on MicroRNA

NCT01510054
View directory record Official record
Conditions
Controlled Ovarian Stimulation
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 31 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2014
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transciptomic Modification Induced by miRNAs in Endometrial Fluid

NCT02554539
View directory record Official record
Conditions
MicroRNA in Endometrial Fluid
Interventions
Endometrial fluid aspiration
Procedure
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Jul 23, 2026, 10:08 AM EDT
Terminated Phase 3 Interventional

A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea

NCT02019589
View directory record Official record
Conditions
Secondary Amenorrhea
Interventions
Progesterone, Placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
22
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors

NCT02552121
View directory record Official record
Conditions
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer (CRPC), Esophagus Cancer, Lung Cancer (NSCLC)
Interventions
Tisotumab vedotin (HuMax-TF-ADC)
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2021 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer

NCT00584857
View directory record Official record
Conditions
Uterine Cancer
Interventions
Paclitaxel ,Carboplatin , Megesterol Acetate
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jul 23, 2026, 10:08 AM EDT
Recruiting Not applicable Interventional

Platelet Rich Plasma for Insufficient Endometrium

NCT05538338
View directory record Official record
Conditions
Infertility of Uterine Origin
Interventions
Platelet Rich Plasma Intrauterine infusion, Normal saline Intrauterine infusion
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 2 Interventional

Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma

NCT01013324
View directory record Official record
Conditions
Endometrial Cancer, Endometrial Neoplasms
Interventions
XL147 (SAR245408)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
10
States / cities
Newport Beach, California • Orlando, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Jul 23, 2026, 10:08 AM EDT
Active, not recruiting No phase listed Observational

Tempus Priority Study: A Pan-tumor Observational Study

NCT05179824
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Bladder Cancer, Lung Cancer, Brain Cancer, Pancreatic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Cancer of Liver, Cancer of Colon, Cancer of Head and Neck, Cancer of Stomach, Cancer of Gastrointestinal Tract, Cancer of Rectum, Cancer of Esophagus, Cancer of Skin, Cancer of Cervix, Cancer of Kidney, Cancer of Larynx, Cancer of Endometrium, Cancer of the Bile Duct, Cancer of Vulva, Cancer of Bone and Connective Tissue, Leukemia, Lymphoma, Spinal Cord Cancer
Interventions
Observation
Other
Lead sponsor
Tempus AI
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 23, 2026, 10:08 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus

NCT00584909
View directory record Official record
Conditions
Uterine Cancer
Interventions
Paclitaxel and carboplatin combination
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Jul 23, 2026, 10:08 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair

NCT02825849
View directory record Official record
Conditions
Infertility, Asherman's Syndrome
Interventions
Intrauterine infusion of platelet rich plasma
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 43 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Not applicable Interventional

Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive

NCT01262040
View directory record Official record
Conditions
Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer, Gastrointestinal Carcinoma, Pancreatic Carcinoma, Lung Cancer, Esophageal Carcinoma
Interventions
Narrow Band Imaging (NBI)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
19 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

NCT02697591
View directory record Official record
Conditions
Advanced Malignancies, Metastatic Cancer
Interventions
INCAGN01876
Drug
Lead sponsor
Incyte Biosciences International Sàrl
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Jul 23, 2026, 10:08 AM EDT
Active, not recruiting Phase 1 Interventional

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

NCT03955978
View directory record Official record
Conditions
Endometrial Cancer, Cancer of the Endometrium
Interventions
TSR-042, Brachytherapy, Endometrial biopsy, Blood draw for immune response
Drug · Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Not applicable Interventional

Investigating the Use of Fluorescence Imaging in Endometrial Cancer Surgery

NCT01562106
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Fluorescence-guided sentinel lymph node detection
Procedure
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Issaquah, Washington • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 2 Interventional Results available

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

NCT03245736
View directory record Official record
Conditions
Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer, Esophagus Cancer, Lung Cancer, Nonsmall Cell, Squamous Cell Carcinoma of the Head and Neck
Interventions
Tisotumab Vedotin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 2 Interventional

Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer

NCT03643510
View directory record Official record
Conditions
Adenocarcinoma of Endometrium
Interventions
Fulvestrant, Abemaciclib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jul 23, 2026, 10:08 AM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

Platelet Rich Plasma Uterine Infusion

NCT06621342
View directory record Official record
Conditions
Infertility, Endometriosis
Interventions
PRP Experimental
Biological
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
23 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 23, 2026, 10:08 AM EDT
Completed Phase 1 Interventional

Whole-Abdominal Radiation Therapy and Cisplatin in Treating Patients With Stage III or Stage IV Endometrial Cancer That Has Been Removed by Surgery

NCT00448643
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Vaginal Brachytherapy, Cisplatin, Whole Abdominal Radiation [WAR] Therapy
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Jul 23, 2026, 10:08 AM EDT
Recruiting Phase 2 Interventional

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

NCT06463028
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sapanisertib, Serabelisib, Paclitaxel
Drug
Lead sponsor
Faeth Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
La Jolla, California • San Francisco, California • Miami Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jul 23, 2026, 10:08 AM EDT